Instem Plc

-10.00 (-1.56%)
Share Name Share Symbol Market Type Share ISIN Share Description
Instem Plc LSE:INS London Ordinary Share GB00B3TQCK30 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -10.00 -1.56% 630.00 44,908 09:31:56
Bid Price Offer Price High Price Low Price Open Price
620.00 640.00 665.00 630.00 640.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Computer Related Svcs, Nec 46.82 1.68 7.60 91.43 143.42
Last Trade Time Trade Type Trade Size Trade Price Currency
16:18:44 O 12,500 625.00 GBX

Instem (INS) Latest News

Instem (INS) Discussions and Chat

Instem Forums and Chat

Date Time Title Posts
18/5/202312:54Instem Life236
26/11/201916:54chevy retail 2501
02/1/201222:19INSULTS...what is the best one ?11
05/1/201016:26Newbie to BB ! any viewpoint30
13/4/200814:52INTERNATIONAL NUCLEAR SOLUTIONS double your money132

Add a New Thread

Instem (INS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-05-31 17:18:45625.0012,50078,125.00O
2023-05-31 17:18:40625.0012,50078,125.00O
2023-05-31 13:17:57630.009505,985.00O
2023-05-31 12:22:18630.001,5859,985.50O
2023-05-31 12:00:22630.003,96624,985.80O

Instem (INS) Top Chat Posts

Top Posts
Posted at 15/5/2023 22:28 by elrico
Adjusted EBITDA loss and net cash outflow resulting from its buy-and-build acquisitions have had an impact on 2022. Investors should focus on what INS has built with accretive acquisitions.

Posted at 28/9/2022 08:20 by tradertrev was the InvestorMeetCompany presentation yesterday afternoon.
However, in the current market mood it's a case of "believe it when you see it" so I suspect we have to wait a couple of months before we see significant share price recovery. Happy to hold for that.

Posted at 21/2/2022 17:22 by km18
...from last year...

Company overview:
Instem plc is a major supplier of technology and services for the healthcare sector. The company is working with 600 clients providing them with shorter R&D cycles, better management controls, effective resource utilization and increased regulatory compliance. INS prides itself with 98% client retention rate and they strive to be not simply a provider of services but a strategic partner to their clients. The limited number of acquisitions mean the balance sheet is light on intangibles and growth is based on a blended approach.
fundamentally the company is strong. Revenue is growing at 11.6% CAGR and “normalised” EPS on Stockopedia is at CAGR of 28.9%. ROCE for last year was at 8.02% and net gearing is negative. Cash generation is strong driven by continuous increase in CFO. Any issues? Valuation would be the biggest, with rolling P/e in the 30s, which is about the average for the sector. P/S is on the higher end at 7.08 and same could be said also for the EV/EBITDA being in the low 30s.
The interim results are showing good performance. Total revenue is up by 41% to £19.8m, of which recurring is £9.9m. PBT is actually below the H1 2020 at £1.2m, leading to lower EPS as well, due to amortisation of intangibles from acquisitions. The company is enjoying continuous transition to the SaaS model which is increasing the visibility of earnings....

...from WealthOracleAM

Posted at 03/9/2021 20:44 by mw8156
good deal of consolidation going on in drug development software, INS having acquired the smaller Swiss competitor and Certara having acquired Pinnacle 21 in the USA.
Posted at 24/5/2021 17:15 by pugugly
Posted at 30/3/2021 15:56 by jombaston
I don't think there are any in the UK, not listed anyway. Phil Reason mentioned a company called Cetara which is NASDAQ listed. They have a $3.9bn mkt cap which is 14x their projected 2021 sales. Instem mkt cap of £133m is 2.7x 2021E revenue. EV/EBITDA Cetara is 38.2x whereas INS is 14.4x.

Their products are more complements than substitutes even though they operate in the same field and obviously you would expect NASDAQ companies to be rated more highly because, er, well, they just are!

Posted at 15/3/2021 22:41 by mw8156
buy price 577 sell price 580 this morning albeit for only 500 maker short of stock?
Posted at 15/11/2020 12:17 by p1nkfish
Back near placing price too.
Posted at 26/6/2020 22:22 by p1nkfish
Interesting statement.

"The 'working from home' impact of COVID-19 has increased the number of conversations that the Group is holding with target principals."

The ability to scale with the SaaS model is attractive. A global platform to promote new capabilities and services from & the market is so fragmented there should be rich pickings to put on the platform.

I have no idea if this will fall back the placing price or below but the statement "The Placing was significantly oversubscribed" makes me think not. The disappointed could buy in the market not much over the placement price.

Posted at 19/2/2020 13:08 by mw8156
large volume, by standards today and yesterday with rising share price, ought to be a bullish signal but have no idea what's going on in the background.
Instem share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230601 02:40:03